SS Innovations International (NASDAQ:SSII) and AtriCure (NASDAQ:ATRC) Financial Analysis

by · The Markets Daily

SS Innovations International (NASDAQ:SSII – Get Free Report) and AtriCure (NASDAQ:ATRC – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Valuation and Earnings

This table compares SS Innovations International and AtriCure”s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SS Innovations International$42.49 million6.37-$12.13 million($0.06)-22.50
AtriCure$534.53 million5.27-$11.45 million$0.30184.37

AtriCure has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SS Innovations International and AtriCure’s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SS Innovations International-23.73%-26.77%-15.01%
AtriCure2.52%4.01%3.03%

Analyst Recommendations

This is a summary of current recommendations and price targets for SS Innovations International and AtriCure, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SS Innovations International10001.00
AtriCure14612.58

SS Innovations International currently has a consensus price target of $7.00, suggesting a potential upside of 418.52%. AtriCure has a consensus price target of $62.30, suggesting a potential upside of 12.64%. Given SS Innovations International’s higher probable upside, equities analysts clearly believe SS Innovations International is more favorable than AtriCure.

Risk & Volatility

SS Innovations International has a beta of -1.52, suggesting that its share price is 252% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Insider & Institutional Ownership

99.1% of AtriCure shares are held by institutional investors. 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

AtriCure beats SS Innovations International on 12 of the 14 factors compared between the two stocks.

About SS Innovations International

(Get Free Report)

SS Innovations International is a medical technology company focused on developing and manufacturing surgical robotic systems. Its flagship product, the SSI Mantra, is a multi-arm platform designed to support surgeons during minimally invasive procedures. The company’s offerings include surgical instruments and related technologies, such as its SSI Mudra instruments, as well as training and support services for hospitals and clinicians. The SSI Mantra system is designed with features including a surgeon console and 3D visualization, and the company has also emphasized remote surgery and telementoring capabilities.

About AtriCure

(Get Free Report)

AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.